Eli Lilly invests $3bn in injectable drug manufacturing facility
Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After the expansion, the facility will rely on automation to accelerate data management and medicine production, which will span manufacturing injectable medicines, device assembly and packaging.